AbbVie stock
Price history
+25.11% over the period1 year: from $234.00 (November 17, 2025) to $292.75 (November 17, 2026), +25.11%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $292.75 |
| October 30, 2026 | $294.89 |
| September 30, 2026 | $261.59 |
| August 31, 2026 | $256.42 |
| July 31, 2026 | $250.94 |
| June 30, 2026 | $251.64 |
| May 29, 2026 | $217.72 |
| April 30, 2026 | $211.32 |
| March 31, 2026 | $217.49 |
| February 27, 2026 | $232.08 |
| January 30, 2026 | $223.01 |
| December 31, 2025 | $228.49 |
| November 28, 2025 | $227.70 |
| November 17, 2025 | $234.00 |
At a glance
The company
Research-based biopharmaceutical company developing and commercializing medicines for autoimmune, inflammatory, cancer, neurological, aesthetic and eye care conditions
Latest results
Quarter to September 30, 2026 · EPS $3.82 (estimate $3.74)
Dividend
TickerLandia's take on AbbVie
- Pricier than usual relative to earnings: P/E on the latest fiscal year 124 vs a median of 27 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 51 vs 42 (+19%) in a group of 10.
- Strong point: Market momentum (86/100 in its group). Weak point: Financial strength (15/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.34% from the 52-week high
Analysts · 29 analysts
Average target$311.81+6.48% vs. price
Buy 23 · Hold 5 · Sell 1 · Buy
TickerLandia Fingerprint: AbbVie
Compared with similar companies: very low risk, very strong momentum, and very low financial strength.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high83
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 50.5 89 EV/EBITDA 18.6 90 Forward P/E 18.2 65 Price/sales 7.89 90 Profitabilityaverage58
How much it earns on revenue and capital.
Metric Value Position in group Net margin 15.7% 46 Gross margin 73.7% 46 Operating margin 36.6% 78 ROA 10.7% 62 Earnings stabilitylow36
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.4% 18 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthhigh63
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +10.30% 62 Earnings growth (year over year) +2,282.10% 98 Average revenue growth (3 years) +1.75% 30 Financial strengthvery low15
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.07 18 Interest coverage 7.30 18 Current ratio 0.87 10 Dividendaverage50
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 14 years 20 Payout ratiopays out more than its earnings 118.7% 81 Dividend yield 2.3% 48 Market momentumvery strong86
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +21.57% 93 Relative strength (6 months) +37.17% 91 1-year return +26.76% 71 Distance from 200-day average +22.15% 91 Riskvery low13
How much the price swings.
Metric Value Position in group Volatility (60 days) 19.7% 9 Beta (1 year) −0.01 16 Maximum drawdown (12 months) 16.5% 14
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
AbbVie is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), AbbVie's P/E today is 124.0, above the median of its last 10 fiscal years (27.2; between 16.8 and 96.8 from 2016 to 2025). AbbVie's P/E (trailing 12 months): 50.5, +19% against the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | AbbVie | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 50.5 | High | |
| Forward P/E | 18.2 | Middle | |
| Operating margin | 36.6% | High | |
| EV/EBITDA | 18.6 | High | |
| Net margin | 15.7% | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: AbbVie. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$17.4B
Latest quarter · Q3 2026
Net income
$4.22B
Latest quarter · Q3 2026
Quarterly net margin
24.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $520.65B
- P/E
- 50.5
- EPS
- $5.83
- Volume
- 4.71M
- Daily trading
- €1.35B
- Dividend yield
- 2.36%
How AbbVie is changing
All resultsRevenue grew 6.0% a year on average over the last 5 years
Operating margin fell from 31.2% to 24.6%
Shares outstanding up 6.0% in 5 years
Returns
AbbVie returns with dividends
$1,000 invested in AbbVie 5 years ago, on November 17, 2021, would be worth $2,982 today with dividends reinvested: +198.25% in total, +24.43% per year. On price alone it would be $2,495 (+149.47%).
| Period | AbbVie | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +3.56% | −3.17% | $1,036 |
| 6 months | +39.18% | +0.11% | $1,392 |
| Year to date | +28.12% | +8.34% | $1,281 |
| 1 year | +28.85% | +11.15% | $1,288 |
| 3 years | +134.04% | +64.30% | $2,340 |
| 5 years | +198.25% | +58.18% | $2,982 |
| 10 years | +613.32% | +239.10% | $7,133 |
Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
AbbVie: technical analysis
AbbVie is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.7% below its all-time closing high ($295.03, November 13, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 59
- Between 30 and 70
- vs 200-session average
- +21.26%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 10, 2026
Support and resistance
Price areas where AbbVie has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$292.82
- Support$279.54−4.54%2 touches, last on November 6, 2026
- Support$267.02−8.81%4 touches, last on September 23, 2026
- Support$260.16−11.15%3 touches, last on October 2, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- −0.00
- Volatility (60 sessions, annualised)
- 19.8%
- Largest fall in the last year
- −16.46%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
AbbVie: seasonality
Average monthly price change over 14 years
Over the last 14 years, the strongest month for AbbVie has been November: +6.38% on average, positive in 10 years out of 13. The weakest has been January: −1.92% on average, positive in 5 years out of 14.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.92% | −3.38% | 5 of 14 |
| February | +3.91% | +3.74% | 12 of 14 |
| March | +0.11% | +1.33% | 10 of 14 |
| April | +0.65% | +1.26% | 8 of 14 |
| May | +0.42% | +0.93% | 9 of 14 |
| June | +1.93% | +0.32% | 7 of 14 |
| July | +1.12% | +0.78% | 7 of 14 |
| August | +0.84% | +1.54% | 8 of 14 |
| September | +1.53% | +1.01% | 8 of 14 |
| October | +1.60% | +4.15% | 9 of 14 |
| November | +6.38% | +7.39% | 10 of 13 |
| December | +2.57% | +0.92% | 9 of 13 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
AbbVie and its competitors
The United States accounts for 76.2% of the sales of AbbVie Inc., while other countries contribute 9.4%, and Germany, Japan, Canada, China, France and the United Kingdom each represent between 1.0% and 2.8%. The company researches, develops, manufactures and sells medicines and therapies worldwide. Its main products include Skyrizi and Rinvoq for autoimmune and inflammatory diseases, Imbruvica, Venclexta and Epkinly for blood cancers, Vraylar for psychiatric disorders, Ubrelvy and Qulipta for migraine, Mavyret for hepatitis C, and Creon, a pancreatic enzyme therapy.
- Headquarters
- North Chicago, United States
- Employees
- 57,000
- Founded
- 2012
- Chief executive
- Robert Michael
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AbbVieABBV | $520.65B | 36.6% | 50.5 | +39.18% |
| Johnson & JohnsonJNJ | $680.19B | 26.6% | 42.9 | +22.93% |
| Merck & Co.MRK | $356.13B | 35.2% | 144.5 | +28.72% |
| AmgenAMGN | $250.07B | 34.1% | 26.8 | +40.34% |
| Eli LillyLLY | $1.28T | 51.3% | 46.5 | +40.86% |
| Gilead SciencesGILD | $207.86B | 38.2% | — | +31.39% |
Same industry or related industries, similar size. Compare AbbVie with its competitors · Full profile
